Fig. 4

Construction and validation of the prognostic CAF-related gene signatures. A, B Coefficient profiles of CAF-related DEGs associated with BCRFS or MFS, and the lambda selection in the LASSO model using ten-fold cross-validation. C, D: Kaplan–Meier survival curve analysis showed the survival of high‐risk and low‐risk patient cohorts divided by BCRFS-related CAF signature or MFS-related CAF signature. E, F The distribution of the risk score, BCRFS or MFS status as well as the expression levels of genes in the BCRFS-related CAF signature or MFS-related CAF signature. G, H ROC analysis showed that the AUCs of BCRFS-related CAF signature or MFS-related CAF signature in predicting the 1-, 2-, and 3- year survival of patients with prostate cancer. CAF Cancer-associated fibroblast, DEGs Differentially expressed genes, BCRFS Biochemical recurrence-free survival, MFS Biochemical recurrence-free survival, LASSO: Least absolute shrinkage and selection operator, ROC Receiver operating characteristic, AUC Areas under the ROC curve